Document:

<PAGE>
                                                                 EXHIBIT 10.27.3

                    FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT

        This FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT (the "Amendment") is made
as of December 14, 2001, between RADIANCE MEDICAL SYSTEMS, INC., a Delaware
corporation (the "Company"), and MICHAEL R. HENSON, an individual ("Executive").

                                    RECITALS

        WHEREAS, the Company currently employs Executive pursuant to that
certain Employment Agreement dated January 14, 1999, as amended on February 1,
1999, December 10, 1999, and December 22, 2000 (the "Employment Agreement");

        WHEREAS, the Executive has voluntarily resigned from his position as
Chairman of the Board of the Company effective December 31, 2001, but will
continue as a member of the Board of Directors; and,

        WHEREAS, notwithstanding any provisions of the Employment Agreement to
the contrary, the Company desires to amend the Employment Agreement to provide
for a continuation of the Executive's salary and benefits through January 31,
2003.

        NOW THEREFORE, in consideration of the mutual agreements and covenants
hereinafter set forth and for other valuable consideration, the Company and
Executive hereby agree as follows:

                                    AGREEMENT

        1. DEFINITIONS.

        Unless otherwise defined herein, capitalized terms used herein shall
have the meanings assigned to them in the Employment Agreement.

        2. PAYMENTS UPON VOLUNTARY RESIGNATION AS CHAIRMAN.

        Notwithstanding anything in the Employment Agreement to the contrary,
the Executive shall be entitled to the following compensation: (i) the portion
of his then-current Base Salary which has accrued through the effective date of
his resignation, (ii) any payments for unused vacation and reimbursement
expenses, which are due, accrued or payable at the effective date of Executive's
resignation, (iii) severance payment in an amount (the "Severance Amount") equal
to Executive's then-current Base Salary, payable pursuant to the Company's
normal payroll procedures through January 31, 2003; (iv) Executive's options to
purchase shares of the Company's common stock and restricted stock shall vest in
accordance with their terms and be exercisable in accordance with same; and (v)
Executive shall be entitled to health and insurance benefits in accordance with
the Company's normal benefits procedures through January 31, 2003.

        3. MISCELLANEOUS.

               (a) Continuing Force and Effect. Except as herein expressly
amended, all terms, covenants and provisions of the Employment Agreement are and
shall remain in full force and effect and all references therein to such
Employment Agreement shall henceforth refer to the Employment

<PAGE>

Agreement as amended by this Amendment. This Amendment shall be deemed
incorporated into, and a part of, the Employment Agreement.

               (b) Counterparts. This Amendment may be executed in any number of
counterparts, each of which shall be deemed an original, but all such
counterparts together shall constitute but one and the same instrument.

        IN WITNESS WHEREOF, we have set our hands hereto as of the date first
above written.

RADIANCE MEDICAL SYSTEMS, INC.

/s/ JEFFREY THIEL
--------------------------------------
Jeffrey Thiel, Chief Executive Officer

EXECUTIVE

/s/ MICHAEL R. HENSON
--------------------------------------
Michael R. Henson

                                       2<PAGE>
                                                                 EXHIBIT 10.29.3

                     THIRD AMENDMENT TO EMPLOYMENT AGREEMENT

        This Third Amendment to Employment Agreement (the "Amendment") is made
as of February 7, 2002, between Radiance Medical Systems, Inc., a Delaware
corporation (the "Company"), and Jeffrey Thiel, an individual ("Executive").

                                    RECITALS

        WHEREAS, the Company currently employs Executive pursuant to that
certain Employment Agreement dated February 1,1999, as amended on December 10,
1999 and December 22, 2000 (the "Employment Agreement"); and

        WHEREAS, the Company is considering a transaction with Endologix, Inc.,
as a result of which is contemplated that the Executive's employment as Chief
Executive Officer of the Company will be terminated; and

        WHEREAS, the Company desires to amend the Employment Agreement to ensure
the Executive's continued employment through and to the closing of any such
transaction with Endologix, Inc. as provided in greater detail below;

        NOW THEREFORE, in consideration of the mutual agreements and covenants
hereinafter set forth and for other valuable consideration, the Company and
Executive hereby agree as follows:

                                    AGREEMENT

        1. DEFINITIONS.

        Unless otherwise defined herein, capitalized terms used herein shall
have the meanings assigned to them in the Employment Agreement.

        2. AMENDMENT TO SECTION 5 OF THE EMPLOYMENT AGREEMENT.

        Section 5 of the Employment Agreement is hereby amended to add a new
Section 5.6 to read in its entirety as follows:

                "5.b TERMINATION UPON CERTAIN TRANSACTIONS. In the event that
        during the term of this Agreement, the Company consummates an
        acquisition of Endologix, Inc., or Endologix, Inc. acquires the Company
        (the "Endologix Transaction"), and Executive's employment as Chief
        Executive Officer of the Company is terminated in connection therewith:

                (a)     the Severance Amount payable pursuant to Section 5.5
                        shall equal Executive's then-current monthly Base Salary
                        multiplied by the greater of (i) thirteen (13) months,
                        or (ii) in the event that Executive's termination is
                        prior to the closing of the Endologix Transaction, that
                        number of months from the date of Executive's
                        termination to the date which is thirteen (13) months
                        after the date of the closing of the Endologix
                        Transaction;

<PAGE>

                (b)     to the extent not covered by Section 5.5, Executive
                        shall continue to receive all benefits during the period
                        set forth in Section 5.6(a)(i) or (ii), whichever
                        applicable; and

                (c)     the Company shall forgive the $100,000 loan made to
                        Executive on or about January 24, 1997, along with all
                        accrued interest thereon.

        In addition, all options not otherwise vested shall continue to vest
        while Executive serves as member of the Board of Directors subsequent to
        the termination of his employment.

        3. OPTIONS. Concurrently with the execution of this Amendment, the
Company shall grant to Executive an incentive stock option for twenty-five
thousand (25,000) shares of the Company's common stock, with an exercise price
equal to the fair market value of such shares on the date hereof, determined in
accordance with the Company's 1996 Stock Option/Stock Issuance Plan. Such
options shall vest one year after the date of grant.

        4. MISCELLANEOUS.

               (a) Continuing Force and Effect. Except as herein expressly
amended, all terms, covenants and provisions of the Employment Agreement are and
shall remain in full force and effect and all references therein to such
Employment Agreement shall henceforth refer to the Employment Agreement as
amended by this Amendment, This Amendment shall be deemed incorporated into, and
a part of, the Employment Agreement.

               (b) Counterparts. This Amendment may be executed in any number of
counterparts, each of which shall be deemed an original, but all such
counterparts together shall constitute but one and the same instrument.

        IN WITNESS WHEREOF, we have set our hands hereto as of the date first
above written.

RADIANCE MEDICAL SYSTEMS, INC.

/s/ JEFFREY O'DONNELL
---------------------------------------
Jeffrey O'Donnell, Chairman of the Board

EXECUTIVE

/s/ JEFFREY THIEL
---------------------------------------
Jeffrey Thiel

                                       2<PAGE>
                                                                 EXHIBIT 10.34.5

BEBIG GmbH                        Amendment V
--------------------------------------------------------------------------------

                                   AMENDMENT V

                       Amendment to the License Agreement

                                     between

                            RMS Medical Systems Inc.
                                 hereafter "RMS"
                   Located at 13700 Alton Parkway, Suite 160,
                       in Irvine, California, 92618, USA

                                       and

                    BEBIG Isotopen- and Medizintechnik GmbH,
                                hereafter "BEBIG"
                        located at Robert-Rossle-Str.10,
                           in D-13125 Berlin, Germany

BACKGROUND

RMS and BEBIG have signed a FACILITY SET-UP AND CONTRACT MANUFACTURING AGREEMENT
Including the ADDENDUM TO FACILITY SET-UP AND CONTRACT MANUFACTURING AGREEMENT
and a LICENSE AGREEMENT (collectively referred to as "the Agreements"), both
amended by the AMENDMENT TO THE FACILITY SET-UP AND CONTRACT MANUFACTURING
AGREEMENT AND THE LICENSE AGREEMENT (referred to as "Amendment I") as well as
Amendment II, Amendment III, Amendment IV, (referred to as such).

RMS desires that BEBIG extends the License Agreement until the 8th of November,
2002.

In light of the above, both parties desire to amend the existing Agreements and
the Amendments I, II, III, and IV as follows:

1.  PAYMENT OF OUTSTANDING INVOICES AND EXTENSION OF LICENSE AGREEMENT:

    RMS will pay to BEBIG a lump sum of US$ 753543 until November 15, 2001, to
    pay all outstanding invoices issued and sent or handed over in Person by
    BEBIG until October 24, 2001 including all open milestone payments. If the
    payment of US$ 753543 has been received until November 15, 2001, BEBIG will
    grant to Radiance an extension of the License Agreement of July 28, 1999
    until November 8, 2002.

2.  LICENSE FEE OFFSETS

    Both parties agree, that amounts to be paid by RMS according to the
    provisions of this Amendment are not subject to offsetting of the license
    fee or royalties as provided by sec. 4 LICENSE AGREEMENT.

<PAGE>

BEBIG GmbH                        Amendment V
--------------------------------------------------------------------------------

3.  MISCELLANEOUS

    a)  All conflict arising under this agreement shall be finally settled in
        accordance with the Arbitration Rules of the German Institution of
        Arbitration e. V. (DIS). The place for Arbitration shall be Frankfurt am
        Main. German law shall be applicable,

    b)  Except as specifically modified by this Amendment V, all terms and
        conditions of the Agreements and Amendment I, II, III, IV shall continue
        uncharged.

Date:  24 October 2001                       Date:  11/1/01

         /s/ ANDREAS ECKERT                          /s/ JEFFREY THIEL
-----------------------------------          -----------------------------------
            BEBIG GmbH                                      RMS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}]]